ArticleCureus2026
Expert Opinion on Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell (BMMSC) Therapy for Knee Osteoarthritis: Clinical Insights, Efficacy, and Safety.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnee osteoarthritis (KOA) remains a major cause of disability. Many patients with moderate disease (Kellgren-Lawrence (KL) grade 2-3) continue to experience disease progression, despite receiving guideline-based conservative treatments that primarily offer symptomatic relief. Allogeneic bone marrow-derived mesenchymal stem cells (BMMSCs) have gained attention for their potential anti-inflammatory, immunomodulatory, and chondroprotective effects. This consensus exercise aimed to capture expert perspectives on diagnostic practices, clinical utility, efficacy, safety, and real-world integration of allogeneic BMMSC therapy.
methodsA structured expert panel comprising experienced orthopedic surgeons reviewed preclinical, clinical, and regulatory evidence supporting allogeneic BMMSCs for KOA. Real-time online polling collected quantitative data on diagnostic approaches, perceived efficacy, safety experience, cartilage-regeneration assessment, and broader orthopedic indications.
resultsMost experts (81.8%) relied on physical examination and X-ray (KL grading) for diagnosis, while MRI was used selectively. A majority (72.7%) considered allogeneic BMMSCs effective for KL grade 2-3 KOA. Routine MRI monitoring for cartilage regeneration was uncommon; only 9.0% reported performing post-procedural MRI for visualizing structural improvements. No severe allergic or anaphylactic reactions were reported, and adverse events were described as mild and transient. Regulatory approval and GMP/GLP-certified manufacturing were viewed as key contributors to both clinician and patient confidence and insurance coverage. Experts supported the use of allogeneic MSCs for cartilage defects and, to a lesser extent, avascular necrosis and tendon or ligament injuries. Identified gaps included long-term durability and standardized rehabilitation protocols.
conclusionsThe expert panel found that allogeneic BMMSCs appear to be a safe and effective treatment for grade 2-3 KOA. Additional real-world data and targeted guidelines are needed to better define the role of allogeneic BMMSCs in routine orthopedic practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.